HOSPITAL UNIVERSITARIO RUBER
Departamento
Universitat Pompeu Fabra
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Pompeu Fabra (13)
2023
-
Clinical characterization and treatment outcomes of follicular cutaneous immune–related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study
Journal of the American Academy of Dermatology, Vol. 88, Núm. 3, pp. 718-720
-
Evaluation of triple negative breast cancer with heterogeneous immune infiltration
Frontiers in Immunology, Vol. 14
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
2022
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2021
-
Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review
Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257
-
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799
2018
-
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer
Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221
-
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 815-826
-
Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
-
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (Clinical and Translational Oncology, (2018), 20, 7, (815-826), 10.1007/s12094-017-1800-5)
Clinical and Translational Oncology
-
Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)
Nature Cell Biology
-
P95HER2–T cell bispecific antibody for breast cancer treatment
Science Translational Medicine, Vol. 10, Núm. 461
2017
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Oncogene, Vol. 36, Núm. 19, pp. 2737-2749